alexa The Protease Fibroblast Activation Protein Is A Potential Biomarker And Therapeutic Target In Diabetes And Fatty Liver Disease
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Mark D Gorrell
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Abstract
Inhibitors of DPP4 enzyme activity are a successful new type 2 diabetes (T2DM) therapy. Non-alcoholic fatty liver disease (NAFLD) is very common in T2DM patients and can progress to involve liver fibrosis. Liver fibrosis is reversible. We are investigating whether the sister protease of DPP4, fibroblast activation protein (FAP), may become a biomarker and therapeutic target in NAFLD. FAP expression by activated fibroblastic cells is predominantly associated with pathological processes including fibrosis severity. Concordantly, natural substrates of FAP include proteins important in fibrinolysis and matrix; alpha2-antiplasmin and collagen. We found that in a diet induced obesity (DIO) model, both DPP4 knockout and FAP knockout mice resist liver damage and have improved glucose tolerance. In T2DM patients, FAP correlated with liver damage markers (ALT, GGT) and liver elastography (FibroScan) score. In obese patients attending hospital for bariatric surgery, FAP correlated with GGT, ALT, AST, iron and ferritin. These associations may reflect FAP shedding from fibroblastic cells in chronic liver injury. Low serum FAP strongly associated with normal elastography scores such that adding FAP to the NAFLD Fibrosis Score algorithm correctly predicted normal elastrography score in two-thirds of T2DM patients. In contrast, serum DPP4, which may be hepatocyte derived, tended to be lower in the T2DM patients and associated with hepatocyte steatosis rather than with fibrosis. FAP is being compared with DPP4, cytokeratin 18 and transferrin in terms of fibrosis prediction. This work may show a new potential clinical application for measuring circulating FAP as a diagnostic and prognostic tool in managing T2DM patients who are at risk of liver fibrosis. FAP assay might also be used to monitor patients following therapeutic intervention. The association of FAP with fibrosis supports the concept that targeting FAP or FAP-expressing cells might be a successful therapeutic in combatting diabetes and alleviating chronic liver diseases.
Biography
Mark D Gorrell is Associate Professor, has a PhD from Australian National University and conducted Postdoctoral studies at University of Melbourne and Johns Hopkins University School of Medicine. He heads a liver disease pathogenesis, dipeptidyl peptidases and diabetes research group in the Centenary Institute and the University of Sydney Medical School. He has authored 112 papers and patents, primarily on DPP4 and related proteases DPP8, DPP9 and fibroblast activation protein and on liver disease pathogenesis. His team uncovered mechanisms of protein binding and of enzyme activity in DPP4. He is treasurer of the International Proteolysis Society and is on 3 editorial boards.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version